Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.ThromboGenics has released six months data from a Phase III program evaluating ocriplasmin as a treatment of symptomatic vitreomacular adhesion (VMA) including macular holes.
Subscribe to our email newsletter
The new data showed that a single injection of ocriplasmin resolved VMA and the visual symptoms associated with it in 29.8% of VMT patients, compared with 7.7% of patients on placebo (28 days).
The results suggested that 10.1% of patients in the ocriplasmin arm gained three lines in visual acuity compared with 5.1% on placebo (6 month follow up).
The data from the trial evaluating ocriplasmin for the treatment of macular hole demonstrated that around 40.6% of patients with full thickness macular hole (FTMH) achieved closure compared with 17% on placebo.
Additionally, 58% of patients with FTMHs smaller than 250µm saw closure with ocriplasmin compared with just 20% in placebo patients.
In the trial, 27% of patients gained = 3 lines in visual acuity after six months of treatment with ocriplasmin, compared with 13% on placebo
Earlier in 2010, ocriplasmin completed two pivotal Phase III trials (TG-MV-006 and TG-MV-007) and met primary endpoint of non-surgical resolution of focal vitreomacular adhesion one month after a single injection of ocriplasmin.
ThromboGenics CEO Patrik de Haes said they remain on track to make regulatory filings for this novel compound in Europe and the US by the year-end.